Glatiramer Acetate in the Reduction of Relapse Frequency in Multiple Sclerosis

被引：0
|
作者：
Miravalle, Augusto [2 ]
Hendin, Barry [3 ]
Vollmer, Timothy L. [2 ]
Kala, Mrinalini [1 ,3 ]
机构：
[1] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 350 West Thomas Rd, Phoenix, AZ 85013 USA
[2] Univ Colorado Hlth Sci, Dept Neurol, Aurora, CO 80045 USA
[3] Univ Arizona, Coll Med, Phoenix, AZ USA
来源：
CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2011年 / 3卷
关键词：
multiple sclerosis; glatiramer acetate; relapse rate;
D O I：
10.4137/CMT.S2057
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Glatiramer acetate (GA; Copaxone (R)) is a heterogeneous polymer of four amino acids. It is one of the therapies approved by the Food and Drug Administration in 1996 for treatment of relapsing remitting multiple sclerosis (RRMS). GA reduces the relapse rate for RRMS, and has a good safety profile and moderate efficacy. Preclinical and clinical studies reveal that GA plays a role in modulating the cells of the immune system as well as in neuroprotection. In this article, we review the role of GA in reducing the frequency of relapses in MS, as well as its efficacy, safety, and current place in therapy.
引用
收藏
页码：151 / 158
页数：8
相关论文
共 50 条
  • [21] Mechanisms of action of glatiramer acetate in multiple sclerosis
    Neuhaus, O
    Farina, C
    Wekerle, H
    Hohlfeld, R
    NEUROLOGY, 2001, 56 (06) : 702 - 708
  • [22] RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
    Kruszewski, Adam M.
    Rao, Gautam
    Tatomir, Alexandru
    Hewes, Daniel
    Tegla, Cosmin A.
    Cudrici, Cornelia D.
    Vingh Nguyen
    Royal, Walter, III
    Bever, Christopher T., Jr.
    Rus, Violeta
    Rus, Horea
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2015, 99 (03) : 498 - 505
  • [23] Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
    Ciriello, Jonathan
    Tatomir, Alexandru
    Hewes, Daniel
    Boodhoo, Dallas
    Anselmo, Freidrich
    Rus, Violeta
    Rus, Horea
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2018, 105 (02) : 175 - 180
  • [24] RGC-32 as a potential marker of relapse and response to treatment with glatiramer acetate in multiple sclerosis
    Rus, H.
    Kruszewski, A.
    Cudrici, C.
    Nguyen, V.
    Royal, W.
    Bever, C.
    Rus, V.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 357 : E17 - E17
  • [25] Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis
    Bourdette, Dennis
    Hartung, Daniel
    JAMA NEUROLOGY, 2015, 72 (12) : 1411 - 1413
  • [26] Can High Doses of Glatiramer Acetate Reduce the Frequency of Its Administration in Multiple Sclerosis?
    Akcay, Halil Ibrahim
    Kurtuncu, Murat
    TURKISH JOURNAL OF NEUROLOGY, 2013, 19 (03) : 121 - 121
  • [27] Panniculitis in multiple sclerosis patients treated with glatiramer acetate
    Sa, J
    Cordeiro, C
    MULTIPLE SCLEROSIS, 2005, 11 : S85 - S85
  • [28] Glatiramer acetate: successful desensitization for treatment of multiple sclerosis
    Bains, Sonia N.
    Hsieh, Fred H.
    Rensel, Mary R.
    Radojicic, Cristine
    Katz, Hary T.
    Inamdar, S. Rubina
    Lang, David M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2010, 104 (04) : 321 - 325
  • [29] Lack of evidence for use of glatiramer acetate in multiple sclerosis
    Munari, LM
    LANCET NEUROLOGY, 2004, 3 (11): : 641 - 641
  • [30] The Use of Interferon Beta and Glatiramer Acetate in Multiple Sclerosis
    Goodin, Douglas S.
    SEMINARS IN NEUROLOGY, 2013, 33 (01) : 13 - 25
12345